References
- Barter PJ , CaulfieldM, ErikssonM et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21) , 2109–2122 (2007).
- Nicholls SJ , TuzcuEM, BrennanDM, TardifJC, NissenSE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation118(24) , 2506–2514 (2008).
- Bruckert E , HayemG, DejagerS, YauC, BegaudB. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther.19(6) , 403–414 (2005).
- Larosa JC , GrundySM, WatersDD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14) , 1425–1435 (2005).
▪ Websites
- The Universite de Montréal Beaulieu-Saucier Pharmacogenomics Centre (2012). www.pgx.ca
- US FDA. 21 Code of Federal Regulations Part 11. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11
- CEPMed. Promoting personalized medicine (2012). www.cepmed.com
- MHICC. The Montreal Health Innovations Centre (2012). www.mhicc.org
- Playing a role in personalized medicine on the world stage – the Montreal Heart Institute becomes Roche global research hub in cardiometabolic disease. www.bloomberg.com/apps/news?pid=newsarchive&sid=aym8II5MA98E